Dr. Kovalchuk received her B. Med. (Honors, 1992) and M.D. (Stomatology, 1994) degrees at the Ivano-Frankivsk National Medical University in Ukraine. In 1994 she began a career at the Medical University and the Chernobyl Research Centre studying consequences of the Chernobyl accident, and in 1998 received a PhD (Medical Genetics). Dr. Kovalchuk conducted extensive postdoctoral training at the Friedrich Miescher Institute and in Novartis/Syngenta (Switzerland). Currently Dr. Olga Kovalchuk is a Professor and a Board of Governors’ Research Chair in Epigenetics of Health and Diseases at the University of Lethbridge, Alberta. In 2008-2018 she held the Canadian Institutes for Health Research – Institute of Gender and Health (CIHR-IGH) Chairs in Gender and Health, and in Gender, Work and Health.  Dr. Kovalchuk is an internationally-renowned leader and an expert in epigenetics and epigenomics of health and disease, environmental epigenomics, and radiation biology and oncology. She is studying mechanisms of disease, epigenetics, novel precision medicine approaches and novel cannabis-based disease therapies. She is a co-founder of the PathwayRx, a research and development medical cannabis company developing personalized approaches for cannabis-based treatment of cancer and age-related diseases.